In last trading session, Zymeworks BC Inc (NASDAQ:ZYME) saw 0.8 million shares changing hands with its beta currently measuring 1.09. Company’s recent per share price level of $13.22 trading at -$0.91 or -6.44% at ring of the bell on the day assigns it a market valuation of $918.10M. That closing price of ZYME’s stock is at a discount of -33.89% from its 52-week high price of $17.70 and is indicating a premium of 39.71% from its 52-week low price of $7.97. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.46 million shares which gives us an average trading volume of 505.37K if we extend that period to 3-months.

For Zymeworks BC Inc (ZYME), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.09 in the current quarter.

Zymeworks BC Inc (NASDAQ:ZYME) trade information

Upright in the red during last session for losing -6.44%, in the last five days ZYME remained trading in the red while hitting it’s week-highest on Friday, 01/03/25 when the stock touched $13.22 price level, adding 22.55% to its value on the day. Zymeworks BC Inc’s shares saw a change of -9.70% in year-to-date performance and have moved -10.55% in past 5-day. Zymeworks BC Inc (NASDAQ:ZYME) showed a performance of 0.61% in past 30-days. Number of shares sold short was 4.34 million shares which calculate 10.0 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 19 to the stock, which implies a rise of 30.42% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would jump 9.23% in reaching the projected high whereas dropping to the targeted low would mean a gain of 9.23% for stock’s current value.

Zymeworks BC Inc (ZYME) estimates and forecasts

Statistics highlight that Zymeworks BC Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 33.94% of value to its shares in past 6 months, showing an annual growth rate of 7.56% while that of industry is 16.50. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 17.71% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 45.2M for the same. And 2 analysts are in estimates of company making revenue of 18.5M in the next quarter. Company posted 16.93M and 10.03M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -6.52% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 16.11% while estimates for its earnings growth in next 5 years are of 11.00%.

Zymeworks BC Inc (NASDAQ:ZYME)’s Major holders

Insiders are in possession of 0.08% of company’s total shares while institution are holding 101.77 percent of that, with stock having share float percentage of 101.86%. Investors also watch the number of corporate investors in a company very closely, which is 101.77% institutions for Zymeworks BC Inc that are currently holding shares of the company.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 2.24 shares of worth $29.57 million or 3.55% of the total outstanding shares. The later fund manager was in possession of 1.42 shares on Oct 31, 2024 , making its stake of worth around $18.81 million in the company or a holder of 2.26% of company’s stock.